ANI Pharmaceuticals Inc — Quarterly Financial Statistics (NASDAQ:ANIP) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities 12.47 M15.86 M34.99 M75.81 M44.05 M30.37 M 185.22 M Cash from investing activities -398.52 M-10.68 M-19.85 M-6.91 M-6.16 M1.4 M -31.52 M Cash from financing activities 291.03 M-4.91 M-9.91 M-1.75 M6.34 M4.64 M -672 K Free cash flow 7.03 M13.38 M15.14 M68.9 M37.89 M28.96 M 150.9 M

Nouvelles

RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus

PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View

TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line

PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View

ANI Pharmaceuticals réalise un bénéfice, les ventes de médicaments pour maladies rares augmentent de 50% | Benzinga France

ANI Pharma T4 2025 : virage vers les maladies rares avec +44% de CA

ANI Pharma Q4 2025 slides: rare disease shift drives 44% revenue growth

Le BPA de ANI Pharma a dépassé les attentes de 0,36$, le CA a surpassé les prévisions

ANI Pharma earnings beat by $0.36, revenue topped estimates

ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50% - ANI Pharmaceuticals (NASDAQ:ANIP)

Brightspring Health Services, BASF, Swiss Re and more set to report Friday

Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up